Larry L. Hillblom Foundation

Larry L. Hillblom Foundation

The Larry L. Hillblom Foundation was created in 1996 from the estate of Larry Lee Hillblom, who co-founded DHL Worldwide Express in 1969 and disappeared in a 1995 plane crash near Saipan. His will directed the bulk of his fortune — estimated at over $500 million — to fund medical research in California. The probate process, however, became a protracted global legal fight after several women from Southeast Asia came forward claiming Hillblom had fathered their children, each entitled to a share under California law. The foundation ultimately received a smaller portion of the estate than originally bequeathed, but the settlement still created a substantial philanthropic endowment. LLHF operates as a California non-profit public benefit corporation that makes grants, not direct investments. It does not deploy capital into venture funds, private equity, or direct company stakes. Its grantmaking focuses exclusively on University of California medical research programs studying diabetes mellitus, metabolic syndrome, and chronic diseases of aging — particularly disorders of the brain and vision. The foundation has funded work at UCSF, UC Davis, UC San Diego, and UCLA, backing both basic science labs and translational research aimed at moving discoveries into clinical application. Its endowment assets are managed as a diversified institutional portfolio invested in limited partnerships. Joseph W. Waechter, a former CEO of DHL, serves as chairman and president, providing continuity from Hillblom's corporate legacy. Peter Donnici, Hillblom's personal attorney and the executor of his estate, serves as chairman emeritus and remains a guiding presence. The foundation maintains a lean operating structure with offices in Petaluma and a satellite location in Kingsburg, California. It participates in the Council on Foundations network, engaging in the Leading Locally conference series alongside other place-based grantmakers. The foundation's structural distinctiveness lies in its origin. Very few American foundations are born from a contested-estate drama that played out across multiple continents and federal courts. That history — combined with a narrow, disease-specific mandate tied to a single state's public university system — makes LLHF an unusual allocator: it is simultaneously a memorial to an enigmatic logistics billionaire and a tightly constrained research-funding vehicle with no programmatic ambition beyond its founding charter.